These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21604567)

  • 1. [Construction of sub-unit dengue vaccines and analysis of its immunogenicity].
    Zhang ZS; Yan YS; Weng YW
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Dec; 24(6):430-2. PubMed ID: 21604567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
    De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
    Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.
    Marcos E; Gil L; Lazo L; Izquierdo A; Brown E; Suzarte E; Valdés I; García A; Méndez L; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2013 Jan; 158(1):225-30. PubMed ID: 22983185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
    Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
    Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
    García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simple production of hydrophobin-fused domain III of dengue envelope protein and induction of neutralizing antibodies against the homotypic serotype of dengue virus.
    Cerezo J; Targovnik AM; Smith ME; González Maglio D; Luppo VC; Morales MA; Miranda MV; Rodríguez Talou J
    Biotechnol Lett; 2020 Mar; 42(3):419-428. PubMed ID: 31828570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.
    Hermida L; Bernardo L; Martín J; Alvarez M; Prado I; López C; Sierra Bde L; Martínez R; Rodríguez R; Zulueta A; Pérez AB; Lazo L; Rosario D; Guillén G; Guzmán MG
    Vaccine; 2006 Apr; 24(16):3165-71. PubMed ID: 16490289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
    Khanam S; Khanna N; Swaminathan S
    Vaccine; 2006 Oct; 24(42-43):6513-25. PubMed ID: 16860446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis.
    Valdés I; Hermida L; Martín J; Menéndez T; Gil L; Lazo L; Castro J; Niebla O; López C; Bernardo L; Sánchez J; Romero Y; Martínez R; Guzmán MG; Guillén G
    Vaccine; 2009 Feb; 27(7):995-1001. PubMed ID: 19100804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model.
    Mellado-Sánchez G; García-Machorro J; Sandoval-Montes C; Gutiérrez-Castañeda B; Rojo-Domínguez A; García-Cordero J; Santos-Argumedo L; Cedillo-Barrón L
    Arch Virol; 2010 Jun; 155(6):847-56. PubMed ID: 20390312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus.
    Lazo L; Gil L; Lopez C; Valdes I; Marcos E; Alvarez M; Blanco A; Romero Y; Falcon V; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2010 Oct; 155(10):1587-95. PubMed ID: 20640909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus.
    Izquierdo A; Bernardo L; Martin J; Santana E; Hermida L; Guillén G; Guzmán MG
    Virus Res; 2008 Dec; 138(1-2):135-8. PubMed ID: 18796319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone.
    Li Z; Yang H; Yang J; Lin H; Wang W; Liu L; Zhao Y; Liu L; Zeng X; Yu Y; Li Y
    Virus Res; 2014 Oct; 191():10-20. PubMed ID: 25091563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.